Celtic Therapeutics Announces the Appointment of New Partner

Celtic Therapeutics Announces the Appointment of New Partner

Media Relations

Celtic Therapeutics L.L.L.P., the global private equity firm focused on novel therapeutic product candidates, today announced that Beth P. Hecht has joined the company as a Partner and Chief Legal and Administrative Officer. Most recently, Ms. Hecht was Senior Vice President, General Counsel and Secretary of The Sun Products Corporation of Wilton, Connecticut.

Ms. Hecht has had more than twenty years experience in the life science industry, serving as a member of the senior leadership team of four life science companies. She was Executive Vice President, General Counsel and Secretary of MedPointe Inc. (formerly known as Carter Wallace Inc.) Prior to MedPointe, Ms. Hecht was Senior Vice President, General Counsel and Secretary of Warner Chilcott PLC, a NASDAQ traded pharmaceutical company. Before Warner Chilcott, she was vice president, general counsel and secretary of ChiRex, Inc., a NASDAQ-traded international specialty pharmaceutical ingredient manufacturer, and Alpharma, Inc., a NYSE multinational pharmaceutical company.

Ms. Hecht was admitted to the New York bar in 1988 and began her legal career as an attorney at the New York offices of the national law firms Willkie, Farr & Gallagher and Kirkland & Ellis where she specialized in corporate transactions and intellectual property law.

Ms. Hecht holds a B.A. degree (summa cum laude) from Amherst College and a J.D. degree (cum laude) from Harvard Law School.

Ms. Hecht will be based at Celtic’s office in New York, NY.

“Beth Hecht is an accomplished counselor and a leader in the life science industry” said Stephen Evans-Freke and Peter B. Corr, Co-Founders and Managing General Partners of Celtic Therapeutics. “She will bring an enormous breadth of experience and talents to her new role and we are delighted to welcome Beth as a Partner to the Celtic Therapeutics team.”

- Ends -

Celtic Therapeutics Management L.L.L.P. was founded in 2007 by Stephen Evans‐Freke and Dr. Peter B. Corr. The Celtic Therapeutics private equity strategy is to acquire promising therapeutic products that have achieved proof of principle in human clinical studies. Celtic Therapeutics’ in-house team of senior pharmaceutical development executives then establishes the clinical, manufacturing, regulatory and commercial strategies for the development of its products and oversees its execution. Upon achieving value enhancing milestones including completing Phase III pivotal studies, Celtic Therapeutics partners with major pharmaceutical companies for continued development and commercialization. Based in the U.S. Virgin Islands, Celtic Therapeutics has origination, acquisition and development operations in New York City and Lausanne, Switzerland. For further information, please visit

Suggested Articles

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.

While screening Caenorhabditis elegans for genetic clues to the PI3K/Akt signaling pathway, scientists found a key protein for insulin synthesis.